Spotify Apple Youtube

Category: Major Meetings

All Podcast Categories
S4-34.5 - GLP-1s and Lean Muscle Loss

S4-34.5 – GLP-1s and Lean Muscle Loss

Stephen Harrison, Mazen Noureddin, Jörn Schattenberg, Louise Campbell and Roger Green unpack compelling drug development stories from this month’s EASL Congress and ADA meetings. This final conversation continues on the subject of evaluating the GLP-1 drug class and its potential impact on lean muscle loss. The final question of Season 4, Episode 34 considers the big picture scope of what has been learned in the last month that might affect research or conceptual thinking going forward.

July 30, 2023
S4-34.4 - Pemvidutide and the Importance of the Actual GLP-1-to-Glucagon Impact Ratio

S4-34.4 – Pemvidutide and the Importance of the Actual GLP-1-to-Glucagon Impact Ratio

Stephen Harrison, Mazen Noureddin, Jörn Schattenberg, Louise Campbell and Roger Green unpack compelling drug development stories from this month’s EASL Congress and ADA meetings. This conversation considers results from the Phase 2b study for the dual GLP-1/glucagon agonist pemvidutide, which wanders into the importance of the actual GLP-1-to-glucagon impact ratio, potentially significant safety signals that remain to be fully studied, and the subject of how much lean muscle mass these agents produce.

July 30, 2023
S4-34.3 - The Increasing Importance of Omics

S4-34.3 – The Increasing Importance of Omics

Stephen Harrison, Mazen Noureddin, Jörn Schattenberg, Louise Campbell and Roger Green unpack compelling drug development stories from this month’s EASL Congress and ADA meetings. This conversation focuses on the increasing importance of omics and potentially powerful weight-loss therapies presented at the ADA meeting. Other major themes in this session include insights on the role of artificial intelligence and epigenetics.

July 29, 2023
S4-34.2 - Practical and Plausible Notes On Injectables Versus Oral Agents

S4-34.2 – Practical and Plausible Notes On Injectables Versus Oral Agents

Stephen Harrison, Mazen Noureddin, Jörn Schattenberg, Louise Campbell and Roger Green unpack compelling drug development stories from this month’s EASL Congress and ADA meetings. This conversation digs deeper into the FASCINATE-2 interim analysis data at week 26 of the 52-week trial. The discussion develops into practical and plausible considerations in a comparison between injectable and oral agents.

July 29, 2023
S4-34 - Drug Development Stories from EASL and ADA: Part 2

S4-34 – Drug Development Stories from EASL and ADA: Part 2

Stephen Harrison, Mazen Noureddin, Jörn Schattenberg, Louise Campbell and Roger Green unpack compelling drug development stories from this month’s EASL Congress and ADA meetings. The session explores a range of topics around the subject of drug development, including notes on orals versus injectables, diabetes medications with potential in the NASH space, new clinical trial data, different drug classes and much more.

July 26, 2023
S4-33.5 - From the Vault: ILC 2022 Looking Back: NASH Is a Complex Disease

S4-33.5 – From the Vault: ILC 2022 Looking Back: NASH Is a Complex Disease

Last year, roughly 5,000 liver community stakeholders gathered in London for the 2022 International Liver Congress (#ILC2022,) the first major hepatology Congress to be held in person since the start of the pandemic (smaller, but very valuable meetings like NASH-TAG, LiverCONNECT and Paris NASH have taken place with an in-person component, but the International Liver Congress and The Liver Meeting have not). This conversation From the Vault revisits still relevant takeaways as the podcast continues its coverage of emerging stories from EASL Congress 2023.

July 23, 2023
S4-33.4 - More Presentation Insights on Frequency of Testing, NITs and Biopsy

S4-33.4 – More Presentation Insights on Frequency of Testing, NITs and Biopsy

Sven Francque and Ian Rowe join Jörn Schattenberg and Roger Green to discuss critical and/or compelling presentations and insights from the recently concluded EASL Congress in Vienna. This final session focuses on another paper by Vincent Wong which sparks discussion around the plausibility of shifting from biopsy to NITs and the cost effectiveness and frequency of testing.

July 23, 2023
S4-33.3 - Steatotic Liver Disease, HCC and Mechanisms of Fibrosis Resolution

S4-33.3 – Steatotic Liver Disease, HCC and Mechanisms of Fibrosis Resolution

Sven Francque and Ian Rowe join Jörn Schattenberg and Roger Green to discuss critical and/or compelling presentations and insights from the recently concluded EASL Congress in Vienna. This session focuses on a study aimed at connecting steatotic liver disease in patients without cirrhosis to HCC outcomes over a ten year period. After, the group unpacks how little is known about the mechanisms of fibrosis resolution.

July 22, 2023
S4-33.2 - Unmet Needs in the Primary Care Setting for Disease Identification

S4-33.2 – Unmet Needs in the Primary Care Setting for Disease Identification

Sven Francque and Ian Rowe join Jörn Schattenberg and Roger Green to discuss the presentations of interest from EASL Congress 2023. In this conversation, Ian points to a presentation on automated FIB-4 score calculation and e-reminders to detect advanced liver disease in patients with type 2 diabetes. The group goes on to explore big picture questions on the topic of disease identification and tease the differences between hepatology and private practices and management of a population-level disease.

July 22, 2023
Stay In Touch
Apple Spotify Youtube

Sponsoring Partnerships

Sponsoring partnerships with SurfingMASH present a multifaceted avenue for companies seeking to amplify their brand presence and engage with targeted audiences.

Learn More